德国拜耳拜瑞妥在国内可以买到吗？

Bayer Germany is suitable for:

1. Adult patients undergoing elective hip or knee replacement surgery to prevent venous thrombosis (VTE).

2. Treat deep vein thrombosis (DVT) in adults and reduce the risk of DVT recurrence and pulmonary embolism (PE) after acute DVT.

3. Adult patients with nonvalvular atrial fibrillation who have one or more risk factors (e.g., congestive heart failure, hypertension, age ≥75 years, diabetes, history of stroke or transient ischemic attack) to reduce the risk of stroke and systemic embolism.

Headquartered in Leverkusen, Germany, Bayer has 750 production plants in 200 locations on six continents; it has 120,000 employees and 350 branches in almost every country in the world. Polymers, medicine and health care, chemical industry and agriculture are the company's four pillar industries. The company's product categories exceed 10,000 types. The company has produced aspirin, heroin, Xarelto and other products.

Is the German Bayer Xarelto available in the country?

Xarelto is already on the market in China, and patients can buy it at major hospitals or pharmacies in the country with a prescription issued by a doctor! 

When it comes to buying medicines, the first thing that comes to mind is the price. Domestic Xarelto is relatively expensive and is not suitable for patients to take it for a long time. It is understood that Xarelto produced by Bayer in Germany has specifications of 20mg*28 tablets and 15mg*28 tablets, and the prices are around 350$. Due to the floating exchange rate, the price is different. Please consult Medical Travel for specific prices!

Purchasing channels: If you want to buy Xarelto that is marketed abroad, but it is inconvenient to go abroad, the most reliable way is to buy it through a formal overseas medical service institution in China, which will sign a guarantee contract for you. The medicine and money will not be handled, and will be mailed to the patient by direct mail, guaranteed to be 100% authentic!

Recommended related hot articles: /newsDetail/88181.html